Condition: Advanced Solid Tumors · Sponsor: BioGate Precision Medicine Corp.
This study is to explore the safety, tolerability, pharmacokinetics, and preliminary efficacy of BGM-2121 in adult patients with advanced solid tumors.
This description comes directly from the study's public registry record.
Queena Hwang · 886-2-2517-6512 · clinical@biogate.com.tw
Always discuss trial participation with your own doctor first.
| National Cheng Kung University Hospital | Tainan, Taiwan | Not Yet Recruiting |
| National Taiwan University Hospital | Taipei, Taiwan | Not Yet Recruiting |
| Taipei Veterans General Hospital | Taipei, Taiwan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07346846